Business
LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING
LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZE...
About this update from Lsl Pharma Group Inc
[{"type":"text","content":"\n\n\nLSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\n\nBOUCHERVILLE, QC, Dec. 23, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (The \"Corporation\" or \"LSL Pharma\"), a Canadian integrated pharmaceutical company, is pleased to announce that it has completed the acquisition (the \"Acquisition\") from Juno Pharmaceuticals LP (the \"Seller\") of all of the outstanding shares of Juno OTC Inc. (\"Juno OTC\"), a Toronto based wholly owned subsidiary of the Seller, for a total purchase price of $5 million (the \"Purchase Price\").\nThe Acquisition was completed pursuant to the terms and conditions of a share purchase agreement dated December 22, 2025 among LSL Pharma, the Seller and Juno OTC (the \"Share Purchase Agreement\"). The Purchase Price was paid as follows: (i) $2,500,000 in cash on December 23, 2025 (the \"Acquisition Closing Date\"); (ii) 5,509,642 Class \"A\" common shares of the Corporation (the \"Common Shares\") on the Acquisition Closing Date; and (iii) $500,000 in cash payable on January 1, 2027 (the \"Purchase Price Balance\"). The Purchase Price Balance is subject to adjustment to reflect variations in working capital, if any.\nThe Corporation acquired full legal ownership of all outstanding shares of Juno OTC on the Acquisition Closing Date. The Seller will retain operational control of Juno OTC, including responsibility for all financial liabilities and business obligations, through December 31, 2025, with the Corporation assuming full control effective January 1, 2026.\nThe Acquisition is an arm's length transaction for the purposes of policies of the TSX Venture Exchange (the \"TSXV\"). No finder's fees are payable in connection with the Acquisition. The Acquisition qualifies as an \"Expedited Acquisition\" under TSXV Policy 5.3 — Acquisitions and Dispositions of Non-Cash Assets and remains subject to final approval by the TSXV. All securities issued in connection with the Acquisition are subject to a statutor...